- Dr. Godino Cosmo
- Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy.
Website | E-mail
- Dr. Andrea Scotti
- Department of Cardiac Thoracic Vascular Sciences and Public Health, University of Padua Medical School, Padua, Italy.
Special Issue Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered by clinicians. From the Framingham Heart Study it was estimated the risk of developing AF that, from age 40 to age 95, was 26 percent for men and 23 percent for women. The prevalence of AF is even greater in the presence of valvular heart disease that is an established risk factor for the occurrence of this arrhythmia. As well as being common, AF has a detrimental impact on outcome (mortality, heart failure, hospitalization, and thromboembolic events), and its clinical relevance becomes even more crucial when AF is associated with structural heart disease and coronary syndromes.
Given the scale of the problem, medical companies have worked to develop devices that meet the needs of these patients. Indeed, one of the priorities was to facilitate the management of patients at high bleeding risk needing an anticoagulation therapy. At the same time, scientific societies have also had to draw up specific guidelines and recommendations concerning this population.
The overall aim of this special issue is to present and discuss the impact and the management of patients with AF undergoing coronary and structural heart interventions.
Submission Deadline15 Jul 2021